# Front Cover

## TL;DR

This study explores how immune checkpoint inhibitors may increase the risk of paraneoplastic syndrome in cancer patients.

## Contribution

It provides real-world insights into the safety profile of immune checkpoint inhibitors.

## Key findings

- Immune checkpoint inhibitors are linked to a higher risk of paraneoplastic syndrome.
- The study uses large-scale real-world data to assess these risks.
- Findings highlight the importance of monitoring patients for immune-related adverse events.

## Abstract

The cover image is based on the article Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study by Bufu Tang et al., https://doi.org/10.1002/cns.70747.